PGT-M

What Is PGT-M?

PGT-M stands for preimplantation genetic testing for monogenic disorders. It is a specialized genetic test used during IVF (in vitro fertilization) to check embryos for a specific inherited genetic condition before an embryo is transferred to the uterus. In plain English, PGT-M helps identify embryos that do not carry a known disease-causing gene change linked to a single-gene disorder.

This matters to people and couples who have a known risk of passing on an inherited condition, such as cystic fibrosis, sickle cell disease, Tay-Sachs disease, Huntington disease, or certain inherited cancer syndromes. For men’s health and fertility, PGT-M often becomes relevant when the male partner is a known carrier of a genetic condition, is affected by an inherited disorder, or has a family history that raises concern before trying to conceive.

At a glance: PGT-M does not improve sperm quality or treat infertility itself. Instead, it is a reproductive screening tool used alongside IVF to reduce the chance of transferring an embryo affected by a known inherited disease.

What Is PGT-M?
Key Takeaways
What Does PGT-M Mean?
How PGT-M Works During IVF
Who Should Consider PGT-M?
Why PGT-M Matters in Fertility Care
What PGT-M Means in Men’s Health and Male Fertility
What Conditions Can Be Tested With PGT-M?
PGT-M vs PGT-A vs Carrier Screening
Accuracy, Limitations, and Risks
What’s Normal vs What’s Not?
PGT-M Process and Timeline
What PGT-M Results Mean
Benefits and Drawbacks
Questions to Ask Your Doctor
Related Tests and Terms
FAQs
References

Key Takeaways

PGT-M is used during IVF to test embryos for a specific inherited single-gene disorder.
It is most relevant when one or both genetic parents are known carriers or affected by an inherited condition.
PGT-M does not test for every possible condition and does not replace prenatal testing during pregnancy.
It usually requires genetic counseling, family history review, and creation of a customized test for the couple or family.
Several embryos may be created, but not all will be suitable, unaffected, or available for transfer.
For men, PGT-M often comes up when there is a male-linked inherited disease, a known gene variant, or abnormal family history.
PGT-M can lower the chance of transferring an affected embryo, but it cannot guarantee a healthy baby.
Results should be interpreted with a fertility specialist and a genetics professional.

What Does PGT-M Mean?

PGT-M stands for:

Preimplantation
Genetic
Testing for
Monogenic disorders

Monogenic means caused by a change in one gene. These are different from chromosomal problems, which involve missing or extra chromosomes. Because PGT-M targets a specific inherited condition, it is highly personalized. The lab is usually looking for a known mutation or pathogenic variant already identified in a parent, a previous child, or another family member.

You may also hear it described as:

Embryo genetic testing for a single-gene disorder
Genetic testing of embryos for inherited disease
Preimplantation testing for a known mutation

The older term PGD (preimplantation genetic diagnosis) is still used in some places, but PGT-M is the more current terminology.

How PGT-M Works During IVF

PGT-M is not a standalone test. It happens as part of an IVF cycle.

Step-by-step overview

Genetic evaluation: A fertility clinic and genetic counselor review your family history, prior genetic test results, and the exact condition being considered.
Test development: A genetics lab may need DNA samples from one or both partners, and sometimes from affected family members, to build a precise assay for that family.
IVF cycle: Eggs are retrieved from the ovaries and fertilized with sperm in the lab.
Embryo growth: Embryos are cultured for several days, often to the blastocyst stage.
Embryo biopsy: A small number of cells are removed from the embryo, typically from the trophectoderm, which later contributes to the placenta.
Genetic testing: The biopsied cells are analyzed for the known genetic condition.
Embryo selection: Embryos not found to carry or be affected by the targeted disorder may be considered for transfer, depending on the inheritance pattern and other factors.
Embryo transfer: One embryo may be transferred in a later cycle, often after freezing and waiting for results.

Why IVF is required

Because the embryo must be tested before pregnancy is established, PGT-M can only be done if embryos are created in the lab. That is why it is tied to IVF rather than natural conception.

Who Should Consider PGT-M?

PGT-M may be considered if:

One partner is a known carrier of a serious recessive genetic disease and the other partner is also a carrier.
One partner has an autosomal dominant condition and there is a 50% chance of passing it on.
The male partner or female partner has an X-linked disorder or is a carrier of one.
A previous child was affected by a known inherited disease.
There is a strong family history of a specific monogenic disorder.
One parent has a known pathogenic variant linked to inherited cancer risk or other serious illness, and the couple wants to reduce the risk of transmission.

Examples of situations where men may encounter PGT-M

A man is a carrier of cystic fibrosis and his partner is also a carrier.
A man has Huntington disease or carries the disease-causing variant.
A man carries a mutation associated with a heritable neuromuscular disorder.
A man has a family history of an X-linked condition relevant to future children.
A couple has discovered a disease-causing variant through carrier screening or prior pregnancy testing.

Why PGT-M Matters in Fertility Care

PGT-M matters because it gives at-risk couples more reproductive options. For some families, it offers a way to pursue pregnancy while lowering the chance of having a child affected by a serious inherited disease.

It may be considered by people who want to:

Reduce the risk of passing on a known genetic condition
Avoid the uncertainty of conceiving naturally and then relying only on prenatal testing
Make embryo selection decisions before transfer
Plan reproduction with more genetic information upfront

That said, PGT-M is not the right path for everyone. IVF is expensive, physically demanding, and emotionally intense. Success rates depend on age, egg quality, sperm factors, embryo development, and how many embryos are available to test.

What PGT-M Means in Men’s Health and Male Fertility

Although PGT-M is usually discussed in the broader IVF setting, it has important implications for men’s reproductive health.

1. It may begin with male genetic testing

A man may first learn about PGT-M after:

Carrier screening before trying to conceive
Infertility testing
A family history review
Testing after recurrent pregnancy loss or an affected child

2. It is separate from sperm testing

PGT-M does not evaluate sperm count, motility, morphology, or DNA fragmentation directly. Those are separate male fertility issues. A man can have excellent semen parameters and still carry a disease-causing variant that puts future children at risk.

3. It may be relevant even without infertility

Some couples seeking PGT-M are not infertile at all. They may be fertile but choose IVF specifically to allow embryo testing for a known inherited condition.

4. Some inherited male conditions can affect fertility too

In some cases, the same underlying genetic issue may also affect reproductive function. Depending on the condition, this could influence:

Sperm production
Hormone balance
Puberty or sexual development
Testicular function

When that happens, fertility specialists may combine genetic planning with male infertility treatment.

What Conditions Can Be Tested With PGT-M?

PGT-M is typically used for disorders caused by mutations in a single gene. The exact list is broad and depends on the lab and clinical situation.

Type of inherited condition	Examples	Why PGT-M may be used
Autosomal recessive disorders	Cystic fibrosis, sickle cell disease, spinal muscular atrophy, Tay-Sachs disease	If both genetic parents are carriers, there is often a 25% chance of an affected child in each pregnancy
Autosomal dominant disorders	Huntington disease, Marfan syndrome, neurofibromatosis, some inherited cancer syndromes	If one parent carries the variant, there is often a 50% chance of transmission
X-linked disorders	Duchenne muscular dystrophy, hemophilia, Fragile X-related scenarios	Risk depends on whether the mother is a carrier or the father is affected and the sex of the embryo
Inherited cancer predisposition syndromes	Some BRCA-related families, Lynch syndrome, familial adenomatous polyposis	May be considered when a known pathogenic variant causes significant inherited health risk

Not every condition is equally straightforward to test. The feasibility of PGT-M depends on:

Whether the disease-causing variant is known
Whether enough family genetic information is available
The inheritance pattern
The lab’s ability to design a reliable testing strategy

PGT-M vs PGT-A vs Carrier Screening

These terms are often confused, but they answer different questions.

Test	What it looks for	When it happens	Main purpose
PGT-M	A specific inherited single-gene disorder	During IVF, before embryo transfer	Reduce risk of passing on a known monogenic disease
PGT-A	Chromosome number abnormalities	During IVF, before embryo transfer	Screen embryos for aneuploidy, such as extra or missing chromosomes
Carrier screening	Whether a person carries mutations linked to recessive or X-linked disorders	Before conception or fertility treatment	Estimate reproductive risk before pregnancy
Prenatal testing	Genetic conditions in an ongoing pregnancy	After pregnancy begins	Evaluate fetal risk or confirm diagnosis

Important distinction

Carrier screening tells you whether you might pass on a condition. PGT-M tests whether a specific embryo appears to carry or be affected by that condition. PGT-A, by contrast, looks at chromosome number rather than a single-gene disease.

Accuracy, Limitations, and Risks

PGT-M is highly sophisticated, but it is not perfect. Results are usually very accurate for the targeted condition when the test is properly developed, yet there are important limitations.

What PGT-M can do well

Target a known disease-causing variant or linked markers
Help identify embryos unlikely to be affected by the specific disorder being tested
Guide embryo selection in families with known inherited disease risk

What PGT-M cannot do

Guarantee that an embryo is completely free of all genetic or medical problems
Detect every possible mutation or condition
Replace routine prenatal care or confirmatory prenatal testing
Compensate for poor embryo quality, low ovarian reserve, or severe sperm-related IVF challenges

Potential limitations

No embryo available: Some IVF cycles do not produce enough embryos for testing or transfer.
No unaffected embryo found: Depending on the inheritance pattern, several embryos may test as affected or carrier status may complicate decisions.
Mosaicism or technical complexity: Embryo biology can be complex, and a few cells may not fully represent the whole embryo.
Test design constraints: Some families need extra DNA samples or a longer setup period before treatment.
Residual risk: Even after PGT-M, a small chance of misdiagnosis or untested conditions remains.

Is embryo biopsy harmful?

Modern embryo biopsy techniques are widely used, but no procedure is completely risk-free. Clinics aim to minimize harm, and biopsy is generally performed by experienced embryology teams. Outcomes depend on the lab, embryo quality, and overall IVF circumstances.

What’s Normal vs What’s Not?

For PGT-M, there is no “normal range” in the same way there is for hormones or semen analysis. Instead, results are interpreted by embryo status.

Result category	What it generally means	Typical next step
Unaffected / negative for targeted disorder	The embryo was not found to have the disease-causing result being tested for	May be considered for transfer, depending on other factors
Carrier	The embryo carries one copy of a recessive variant but is usually not expected to be affected	May or may not be considered transferable based on condition, clinic policy, and patient preference
Affected / positive	The embryo appears to have the targeted genetic condition or pathogenic genotype	Typically not selected for transfer
Inconclusive / no result	The test did not provide a clear answer	Depends on clinic policy, retesting options, and embryo availability

What counts as a suitable embryo for transfer can depend on more than PGT-M alone. Other factors may include:

Whether the embryo is chromosomally normal if PGT-A was also performed
Embryo developmental quality
Clinic-specific protocols
The family’s preferences around carrier embryos

PGT-M Process and Timeline

Couples are often surprised that PGT-M requires planning well before the IVF cycle itself.

Typical timeline

Preconception or fertility consultation – review of family history and prior genetic results
Genetic counseling – discussion of inheritance, testing options, and limitations
Lab setup – creation and validation of the family-specific test, which can take weeks or sometimes longer
IVF stimulation and egg retrieval
Fertilization and embryo culture
Embryo biopsy and freezing
Genetic analysis and reporting
Frozen embryo transfer of a selected embryo, if available

Because of this lead time, anyone considering PGT-M should ideally start discussions early rather than waiting until the IVF cycle is already underway.

What PGT-M Results Mean

PGT-M results are usually reported in relation to the specific disorder under investigation. The report may classify embryos as:

Unaffected
Carrier
Affected
Indeterminate or inconclusive

How results affect decision-making

The next step depends on the couple’s goals and the genetics involved:

If the disorder is severe and the embryo is affected, it is typically not chosen for transfer.
If the embryo is unaffected, it may move forward for possible transfer if other IVF criteria are met.
If the embryo is a carrier, choices can be more nuanced. For recessive diseases, carrier embryos are often healthy, but decisions vary by family and clinic.
If the result is unclear, some embryos may not be usable or may require more counseling.

Does a normal PGT-M result guarantee a healthy baby?

No. PGT-M only addresses the targeted condition and does not screen out every medical issue, birth defect, developmental disorder, or future illness. This is one of the most important points for patients to understand.

Benefits and Drawbacks of PGT-M

Potential benefits

Can reduce the likelihood of transferring an embryo affected by a known inherited disorder
Offers reproductive planning for families with specific genetic risks
May reduce the need to face certain decisions later in pregnancy
Can provide more clarity before embryo transfer

Potential drawbacks

Requires IVF, even for couples without infertility
Can be costly and time-intensive
May yield few or no transferable embryos
Can create difficult ethical or emotional decisions
Does not replace prenatal testing or guarantee a healthy child

Common Misconceptions About PGT-M

Myth: PGT-M is the same as general embryo health screening

Reality: PGT-M looks for a specific single-gene disorder. It is not a universal health screen.

Myth: If an embryo passes PGT-M, no prenatal testing is needed

Reality: Professional societies typically recommend discussing confirmatory prenatal testing because no preimplantation test is perfect.

Myth: PGT-M can fix male infertility

Reality: It does not improve sperm count, motility, testosterone, or natural fertility. It is a reproductive genetics tool, not a treatment for semen abnormalities.

Myth: PGT-M is only for women with fertility problems

Reality: Many couples using PGT-M are addressing inherited disease risk rather than infertility. Male genetic status may be the main reason the couple seeks the test.

When to Talk to a Fertility Specialist or Genetic Counselor

You should consider professional evaluation if:

You or your partner are known carriers of the same recessive disease
You have a personal diagnosis of an inherited condition
You have a strong family history of a genetic disorder
You had a previous pregnancy or child affected by a genetic disease
Carrier screening found a pathogenic variant and you are planning pregnancy
You want to understand IVF with genetic testing before trying to conceive

In many cases, the best starting point is a reproductive endocrinologist, fertility clinic, or genetic counselor. If male-factor issues are also present, a male fertility urologist may be part of the care team.

Questions to Ask Your Doctor

Is PGT-M appropriate for our specific genetic risk?
Do we need additional carrier testing or confirmatory genetic testing first?
How is the test built for our family, and how long will setup take?
Will carrier embryos be considered for transfer in our case?
Should we also consider PGT-A, or is that a separate decision?
What is the chance that we will have no unaffected embryos available?
What are the limitations of this test for our condition?
Do you recommend prenatal testing even if the embryo is cleared by PGT-M?
How do sperm quality, egg quality, and age affect our chances of success?
What are the emotional, financial, and ethical considerations we should plan for?

IVF: The assisted reproduction process required to create embryos for PGT-M.
Carrier screening: Blood or saliva testing that checks whether someone carries gene variants linked to inherited diseases.
PGT-A: Embryo testing for chromosome number abnormalities, not specific single-gene disorders.
Embryo biopsy: Removal of a few cells from an embryo for testing.
Monogenic disorder: A condition caused by a pathogenic variant in one gene.
Autosomal recessive / dominant / X-linked inheritance: The main inheritance patterns used to estimate risk to future children.
Prenatal diagnostic testing: Tests during pregnancy, such as chorionic villus sampling or amniocentesis, that may confirm fetal genetic status.

Frequently Asked Questions

Is PGT-M the same as PGD?

Mostly, yes. PGD is the older term, and PGT-M is the current term more commonly used by professional societies and fertility clinics.

What does PGT-M test for?

PGT-M tests embryos for a specific known inherited single-gene condition, such as cystic fibrosis or Huntington disease. It does not test for every genetic problem.

Can PGT-M be used if only the father is a carrier?

Yes, depending on the condition. The risk to the embryo depends on the inheritance pattern and whether the other genetic parent is also a carrier or affected.

Does PGT-M improve IVF success rates?

Not directly. Its goal is to reduce the chance of transferring an embryo affected by a targeted genetic disorder. Whether it improves live birth outcomes depends on many factors beyond the genetic test itself.

How accurate is PGT-M?

It is generally highly accurate for the specific condition being tested when the assay is properly designed and validated, but it is not perfect. There is still residual risk, which is why prenatal confirmation is often discussed.

Can PGT-M tell if an embryo is a carrier?

Often, yes. For many recessive conditions, the report can distinguish between unaffected non-carrier embryos, carrier embryos, and affected embryos. Whether carrier embryos are considered for transfer depends on the clinical context.

Do you need IVF to do PGT-M?

Yes. Because the embryo must be tested before pregnancy is established, PGT-M requires IVF to create embryos in the lab.

Should prenatal testing still be done after PGT-M?

Many specialists recommend discussing confirmatory prenatal testing because PGT-M does not eliminate all uncertainty and does not evaluate every possible fetal condition.

Can PGT-M test for infertility genes or all future health problems?

No. PGT-M is targeted. It is not a broad prediction tool for overall health, intelligence, personality, or all possible diseases.

Who decides which embryo gets transferred?

The decision is typically made by the patient or couple with guidance from the fertility specialist and genetics team, based on embryo test results, embryo quality, reproductive goals, and clinic policy.

References

American Society for Reproductive Medicine (ASRM). Guidance and committee opinions on preimplantation genetic testing.
European Society of Human Reproduction and Embryology (ESHRE). Good practice recommendations for preimplantation genetic testing.
American College of Obstetricians and Gynecologists (ACOG). Committee guidance on preimplantation genetic testing and prenatal screening/diagnosis.
Society for Assisted Reproductive Technology (SART). Patient education resources on IVF and embryo testing.
National Human Genome Research Institute (NHGRI). Educational resources on genetic disorders and inheritance.
MedlinePlus Genetics. Trusted patient information on inherited conditions and genetic testing terminology.